The CTC-based oncology diagnostics firm raised $15.6 million in net proceeds from a public offering of its securities in February.
The assays use specimens from symptomatic patients for the qualitative detection and differentiation of HSV-1 and HSV-2 with results generated within one hour.
The firm received CLIA waiver of a strep A assay on its Liat platform yesterday, and a favorable evaluation of its influenza A/B assay was published last week.
Low-pass sequencing and digital PCR analysis of cell-free circulating tumor DNA could detect metastatic disease in primary breast cancer patients months before clinical diagnosis.
The point-of-care Roche cobas Liat Strep A assay can now be run in physician's offices and pharmacy clinics.
In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.
Hong Kong is using DNA phenotyping to shame litterers.
A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.
NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.